Search

HAPLO-iPS • COST ACTION CA21151

WG5 • Management, data handling and Ethics

Data handling and Ethics

Working group 5 will establish a consensus on the management of data handling and protection as well as ethical core documents for donation and clinical use of cord blood-derived hiPSC. WG5 is also responsible for the organization of Working Groups including identification of critical dependencies between their objectives.

Objectives

WG5 Leaders

CG-_0005_Joel Glover
Joel C. Glover
WG5 Leader
University of Oslo
joel.glover@medisin.uio.no
Norway
Norway
CG-_0002_Peter Bauer
Peter Bauer
WG5 Co-leader
Bioinova
peter.bauer@bioinova.cz
Czechia
Czechia

Description of Work

T5.1

Management Group meeting for Working Group organisation.

T5.2

Experts meeting for data categorisation (e.g., Patent issues, licensing, know-how) and data confidentiality (donor personal data e.g., genetic sequence, donor treatment). Analysis of ethical, legal and social implications.

T5.3

Literature review and experts meeting for agree on CB biobank Informed Consent templates and information provided for donors.

T5.4

Experts meeting: review of CB registry and forward planning.

Deliverables and milestones

D5.1

Report on the activity and management co-ordination and progress monitoring plan (M6).

D5.2

Publication of guidelines for the management of data collection and protection (M30).

D5.3

Proposal for HAPLO-iPS Consent Form and Information sheet to be signed by donors (M21).

M5.1

Organisation of the Working Groups including identification of critical dependencies between Working Group objectives.

M5.2

Consensus document for consent form and information sheet for donors following ethical criteria.

WG5 Participants

Adel Meguireche
Working Group: WG1, WG2, WG3, WG4, WG5, WG6, WG7
University badji Mokhtar Annaba Algeria
Algeria
Algeria
Andreas Kurtz
Working Group: WG3, WG5, WG6
Fraunhofer Institute for Biomedical Engineering
Germany
Germany
Emiran Defne Atay
Working Group: WG1, WG2, WG3, WG4, WG5, WG6, WG7
Acibadem Mehmet Ali Aydinlar University
Turkey
Turkey
Isabella Nacu
Working Group: WG1, WG2, WG3, WG4, WG5, WG6, WG7
University of Medicine and Pharmacy "Grigore T. Popa" Iasi
Romania
Romania
Daniel Besser
Working Group: WG2, WG5
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
Germany
Germany
Daniel Naumovas
Working Group: WG3, WG4, WG5, WG7
Vilnius University, Life Sciences Center
Lithuania
Lithuania
David Morrow
Working Group: WG4, WG5, WG6
EATRIS
Netherlands
Netherlands
Deborah Mascalzoni
Working Group: WG5
Eurac Research
Italy
Italy
Diana Chaker
Working Group: WG1, WG2, WG3, WG4, WG5, WG6, WG7
CITHERA
France
France
Dinko Mitrecic
Working Group: WG1, WG2, WG5, WG6
University of Zagreb
Croatia
Croatia
Çisem Yeşil Kayabaşı
Working Group: WG1, WG2, WG3, WG5, WG6
Gazi University Faculty of Medicine
Turkey
Turkey
Helen Papadaki
Working Group: WG1, WG3, WG5, WG6, WG7
University of Crete
Greece
Greece
Loading more